Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - NeuBase Therapeutics, Inc. | Financial_Report.xls |
| EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - NeuBase Therapeutics, Inc. | ex-32_1.htm |
| EX-31.2 - CERTIFICATION OF INTERIM CHIEF FINANCIAL OFFICER - NeuBase Therapeutics, Inc. | ex-31_2.htm |
| EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - NeuBase Therapeutics, Inc. | ex-31_1.htm |
| 10-Q - QUARTERLY REPORT - NeuBase Therapeutics, Inc. | ohrp-10q_123112.htm |
Exhibit 32.2
Certification of Chief Financial Officer
Pursuant to 18 U.S.C Section 1350,
As Adopted Pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002
Not Filed Pursuant to the Securities Exchange Act of 1934
In connection with the Quarterly Report of Ohr Pharmaceutical, Inc. (the “Company” ) on Form 10-Q for the period ending June 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report” ), I, Sam Backenroth , Chief Financial Officer, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
|
1.
|
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
|
2.
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Dated: February 19, 2013
|
/s/ Sam Backenroth
|
|
|
Name: Sam Backenroth
|
|
|
Title: Chief Financial Officer
|